This is a research article published in Clinical & Molecular Biomedicine. It studies resveratrol as a potential inhibitor of MARK4 using docking, fluorescence binding, kinase inhibition, and cell proliferation assays.

The work combines computational and experimental approaches and frames MARK4 inhibition as relevant to both cancer and neurodegenerative disease.

The introduction describes protein kinases as central regulators of cellular signaling and highlights their relevance to malignant transformation, metastasis, and therapy resistance.

MARK kinases are introduced as AMPK-family members involved in microtubule stability, cytoskeletal reorganization, vesicle trafficking, polarity, and mitotic spindle organization. MARK4 is emphasized as a particularly important isoform because of its association with cancer, neurodegeneration, and metabolic imbalance.

The paper argues that selective inhibition of MARK4 could disrupt both structural and signaling components of tumor progression and reviews prior work suggesting that natural compounds such as rosmarinic acid, myricetin, and bacopaside II can modulate MARK4.

Resveratrol is then proposed as a suitable candidate because of its pleiotropic signaling effects and documented antioxidant, anti-inflammatory, neuroprotective, and anticancer activities.

The methods combine molecular docking with protein expression and purification, ATPase-based enzyme inhibition, fluorescence binding studies, and H1299 cell proliferation analysis.

MARK4 docking used the human crystal structure from the PDB (5ES1). Protein preparation included removal of co-crystallized ligands and water molecules, hydrogen addition, and charge assignment before blind docking with InstaDock.

Experimental work included recombinant MARK4 expression in E. coli M15 cells using a pQE30 vector system, enzyme inhibition analysis with BIOMOL green reagent, fluorescence quenching measurements on a Jasco spectrofluorometer, and MTT-based cell viability analysis in H1299 lung cancer cells.

Docking suggested that RV occupies the MARK4 catalytic pocket and interacts with residues Ile62 and Glu133 through conventional hydrogen bonds, along with multiple hydrophobic, van der Waals, and π–alkyl contacts.

Fluorescence binding studies showed progressive quenching with increasing RV concentration and were interpreted as evidence of direct binding with an estimated association constant of 7.0 × 10^4 M−1.

In the kinase assay, MARK4 activity decreased as RV concentration increased, and the reported IC50 was approximately 7 µM.

In H1299 cells, RV reduced cell proliferation over 48 hours and the reported IC50 was approximately 114 µM.

The article concludes that resveratrol is a promising phytochemical scaffold for MARK4 targeting because it shows structural compatibility in docking, measurable direct binding in fluorescence experiments, functional kinase inhibition, and cytotoxic effects in H1299 cells.

The authors further argue that MARK4–resveratrol interaction provides a useful starting point for rational drug design aimed at multi-pathway therapeutic intervention in cancer and related diseases.

The conclusion also notes translational challenges for natural compounds, including bioavailability, metabolism, and potency, and points to medicinal chemistry, structural biology, and nanotechnology-based delivery as future directions.

The closing section includes statements for competing interests and data availability.